Research & Education

Emerging Therapy Options in Immunotherapy for NSCLC

December 20, 2016 at 9:00PM EST

Immunotherapy is now a standard option for treatment of patients with non-small cell lung cancer and has been shown to improve survival compared to chemotherapy in a subset of patients. This

IASLC Chicago Multidisciplinary Symposium and ESMO 2016 Annual Meeting: 2016 Review

November 16, 2016 at 9:00PM EST - Recording Available

Recent meetings of the European Society of Medical Oncology (October 7-11, 2016) and the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology (September 22-24, 2016) provided important updates and new information relative to the multidisciplinary management of patients with lung cancer.

Mesothelioma: Causes, Prevention, Screening and Early Detection

November 15, 2016 at 9:00PM EST - Recording Available

A recent IASLC webinar (July 27, 2016 - available on demand at www.IASLC.org) addressed the role of surgery for malignant mesothelioma and updated the status of systemic therapy of this disease. Despite advances in treatment, this disease remains a formidable challenge.

Management of ALK Patients With NSCLC: A Multidisciplinary Approach

September 12, 2016 at 8:00PM EST; September 14, 2016 at 9:00PM EST; September 16, 2016 at 11:00PM EST - Recordings Available

This sixty-minute webinar will feature 3 presentations. The webinar is being presented at three different times and features the same three speakers.

IASLC Lung Cancer Grand Rounds: Advances in Lung Cancer Imaging

August 16, 2016 at 9:00PM EDT - Recording Available

This live session of IASLC Lung Cancer Grand Rounds features Dr. Brett Carter. This presentation will discuss the role of advanced imaging techniques in evaluating lung cancer.

Malignant Pleural Mesothelioma - Multidisciplinary Treatment Update

Wednesday July 27, 2016 9:00PM EDT - Recording Available

Malignant Pleural Mesothelioma (MPM) remains one of the most intractable malignancies with current overall survival (OS) of about 12 months in unresectable advanced stages. Multimodality therapy in resectable patients yields median OS of 17-25 months. Recently, the field has made several advances due to novel discoveries and initiatives in epidemiology, screening/detection and treatment.

Radiation Oncology Highlights: ASCO 2016

July 7, 2016 6:00PM CEST - Recording Available

This program will review radiation therapy for lung cancer highlights from the recent 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The focus of the presentations are upon the most relevant data and reports that impact current standards of care in the radiotherapeutic management of non-small cell lung cancer (NSCLC).

Treatment of Patients With EGFR-Mutant NSCLC

July 5, 2016 at 6:00 PM CEST - Recording Available

Patients harboring EGFR mutations represent a subgroup of non-small cell lung cancer (NSCLC) with high sensitivity to EGFR-Tyrosine kinase inhibitors. Many agents are currently available in clinical practice with small differences in terms of efficacy and toxicity profile.

Implementing and Integrating a CT Screening and Smoking Cessation Program

June 30, 2016 9:00PM EDT - Recording Available

"Implementing smoking cessation in lung cancer screening settings: Opportunities and Challenges"

IASLC Lung Cancer Grand Rounds: Advances in Treatment of Lung Cancer - 2016 Update

June 28, 2016 at 9:00 PM EDT - Recording Available

This live session of IASLC Lung Cancer Grand Rounds features Dr. Mark Socinski. Dr. Socinski will highlight recent data in lung cancer, presented during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The program will focus on scientific and clinical progress most likely to impact the current management of patients with lung cancer.

Pages